IMM-1-104 + pembrolizumab

IMM-1-104 + pembrolizumab is an investigational drug combination under clinical evaluation for advanced or metastatic solid tumors, specifically in RAS-mutated or RAS/MAPK-activated cancers. IMM-1-104 is an orally available, selective dual MEK1/2 inhibitor that targets the MAPK pathway in cancer cells, aiming to reduce tumor growth with a differentiated "deep cyclic inhibition" approach. Pembrolizumab is a monoclonal antibody that blocks PD-1 (programmed cell death protein 1), an immune checkpoint, thereby enhancing T-cell mediated anti-tumor activity. The combination is being studied for synergistic anti-tumor effects, especially in malignancies driven by RAS mutations, such as pancreatic cancer, melanoma, and non-small cell lung cancer[1][3][5].

Other names

MK-3475MK3475MK 3475lambrolizumab